

Prostatype Genomics publishes newsletter on progress in the US and in Europe

In this edition, the company's CEO talks more about the recently submitted application for Medicare approval of reimbursement in the US market and the ongoing study with American patients, paving the way for a planned sales effort starting in 2025. The recently obtained IVDR certification in Europe is also highlighted, which constitutes an important regulatory milestone.

Content of the newsletter:

- Medicare application submitted and the processing is ongoing
- All patients in the US study with Prostatype® will have been analysed shortly
- Filmed presentation with the company's Chief Medical Officer Professor Gerald Andriole
- Prostatype Genomics to participate at Redeye Technology & Life Science Day on December 3
- The US market for Prostatype® has great advantages compared to Europe
- Prostatype® can contribute with 600 MSEK in annual health economy benefit just in Sweden according to a study by IHE
- Prostatype Genomics presents its business plan for the US market
- Obtained IVDR certification: another important regulatory milestone achieved

Read the full newsletter and subscribe via this link:

<https://bit.ly/progenov24en>

Prostatype Genomics' newsletter is published to offer broader and more in-depth information about the company's operations and progress. It is produced together with the IR communications agency Honeybadger, <https://www.honeybadger.se/en/>

For more information, please contact:

Fredrik Rickman, CEO Prostatype Genomics AB

Telephone: +46 (0)73 049 77 01

Email: fredrik.rickman@prostatypegenomics.com

About Prostatype Genomics AB

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.